Advertisement
Otro candidato a vacuna contra la COVID-19 inicia los ensayos clínicos finales

AstraZeneca Vaccine Guards Against Severe COVID-19 Illness

0

Researchers also found that a single dose of the vaccine was 76 percent effective at preventing COVID-19

HealthDay Reports: Have Lockdown Measures Worked to Control Coronavirus? Here's the Evidence

Mutation That Helps Coronavirus Evade Vaccines Showing Up in British Variant

0

Worrisome mutation known as E484K appears to have arisen in 11 of more than 200,000 B.1.1.7 coronavirus variant samples in the United Kingdom

Perioperative Chemo Feasible for Resectable Pancreatic Cancer

0

Phase 2 randomized trial revealed similar overall survival for two active regimens compared with adjuvant therapy

ASH: Daratumumab + Pomalidomide

>60 Percent Receiving COVID-19 Vaccine in U.S. Are Non-Hispanic Whites

0

Of those having received their first dose by Jan. 14, 2021, 63.0 percent were women, 55.0 percent were aged 50 years and older

Lo que usted debe saber sobre las vacunas contra la COVID

Moderna Wants to Increase Number of Doses in COVID-19 Vaccine Vials

0

However, there are potential downsides to putting more vaccine in each vial

SB - 2/2 -- Improvements in ICU COVID Treatments May Have Plateaued

Dexmedetomidine No Better Than Propofol for Adults With Sepsis

0

For light sedation of mechanically ventilated patients with sepsis, number of days alive without delirium or coma similar between groups

Regular Aspirin Use Before Diagnosis May Cut CRC Mortality

0

Long-term aspirin use before diagnosis also linked to lower odds of diagnosis with distant metastases

Rifaximin Prevents Overt Hepatic Encephalopathy After TIPS

0

For patients with cirrhosis, rifaximin reduces odds of overt HE after transjugular intrahepatic portosystemic shunt

U.S. Awards Contract for COVID-19 Home Test Kit

0

With the product from Australian company Ellume, users can swab themselves at home and check their status in about 20 minutes

Marijuana Use Tied to Self-Harm, All-Cause Death in Youth With Mood Disorders

0

Analysis included youth 10 through 24 years of age with mood disorder; 10.3 percent had documented cannabis use disorder